The development of surgical treatment in liver and biliary tract diseases
Authors:
Z. Krška; J. Šváb; J. Ulrych
Authors place of work:
I. chirurgická klinika 1. LF UK a VFN v Praze, přednosta: prof. MUDr. Z. Krška, CSc.
Published in the journal:
Rozhl. Chir., 2012, roč. 91, č. 9, s. 464-468.
Category:
Original articles
Summary
Introduction:
Surgical liver and biliary tract diseases remain to be among the most serious and the incidence of illnesses requiring surgical treatment has been increasing. It is therefore essential to consider the new possibilities of oncological and miniinvasive care, including ablation treatment, and to evaluate their importance and integration in the treatment system.
Material and methods:
The article presents a retrospective analysis of three consecutive sets of patients from 1991–2011. Our monitoring focused primarily on bile duct lesions and on primary and secondary tumours of the liver. Assessments included the extent and method of the operation, neoadjuvant and adjuvant care, complications, lethality, and survival rate.
Results:
Our study confirmed that the number of surgically treated secondary tumours (colorectal carcinoma metastases) rose by 9% as a result of downstaging (i.e., the combination of chemotherapy and oncological treatment or RFA) and the use of embolization via the portal vein and sequential resections. With no fundamental changes recorded in hepatocellular carcinoma treatment, resection or transplantation still appears to be the only curative treatment method. One-year survival is minimal without these procedures. We recorded a slight increase in the incidence of cholangiocarcinoma from 6 to 10.3%. The results of extrahepatic and hepatic form resections range from 0 to 90%, depending on the stage of the disease. Biliary duct lesions are treated more frequently at the time of laparoscopic surgery; they are diagnosed later or when stenosis has already developed, and hepaticojejunoanastomosis is the most widely applied procedure in treating the lesions. The authors indicate the ablation methods in hepatic and bile duct tumour treatment only when resection treatment is not possible.
Conclusion:
Surgical resection treatment in malignant diseases of the liver and biliary tract remains the primary treatment method with a high curative potential. Neoadjuvant combined treatment increases the eligibility of patients for such surgical procedures. In biliary tract lesions, we also regard the surgical approach as dominant. The overview of results for individual periods implies the necessity of interdisciplinary care in order to achieve better results in surgical management.
Key words:
liver and bile duct surgery – hepatocellular carcinoma – cholangiocarcinoma – bile duct lesion – downstaging
Zdroje
1. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminář Liver Dis 1999;19:329–328.
2. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer 2010,27;102(9):1313–8.
3. Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol 2011;16(5):452–63.
4. Maroulis I, Karavias DD, Karavias D. General principles of hepatectomy in colorectal liver metastases. Tech Coloproctol 2011;15Suppl1:S13–6.
5. Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003;20 (6):481–96.
6. Shimada H, Tanaka K, Matsuo K, Togo S.Treatment for multiple bilobar liver metastases of colorectal cancer. Langenbecks Arch Surg 2006;391(2):130–42.
7. Nikfarjam M, Shereef S, Kimchi ET et al. Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol 2009;16(7):1860–7.
8. Scoggins CR, Campbell ML, Landry CS et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009;16(1):35–41.
9. Chaudhury P, Hassanain M, Bouganim N et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) 2010;12(1):37–42.
10. Hebbar M, Pruvot, FR, Romano O et al. Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer. Cancer Treat Rev 2009; 35(8):668–75.
11. Chemotherapy of metastatic colorectal cancer. Prescrire Int. 2010; 19(109):219–24.
12. García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12(8):533–42.HCC
13. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225–235.
14. Brůha R et al. Diagnostika a léčba hepatocelulárního karcinomu. Vnitř Lék 2005;12:140–1408.
15. Belghiti J. Resection and liver transplantation for HCC. J Gastroenterol 2009;44,Suppl19:132–135.
16. Bruix J, Herman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
17. Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006; 60(2):89–98.
18. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134(6):1752–63.
19. Masuzaki R, Omata, M. Treatment of hepatocellular carcinoma. Indian J Gastroenterol 2008;27(3):113–22.
20. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7 (3):237–57.
21. Samuel M, Chow PK, Chan Shih-Yen E et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009;21(1):CD001199.
22. Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation.Transplant Proc 2009;41(10): 4023–35.
23. Dinant S et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor) Ann Surg Oncol 2006;13,6: 872–880.
24. Van Gulik TM et al. Original article: New surgical approaches to the Klatskin tumour. Aliment Pharmacol Ther 2007;26,Suppl2: 127–32.
25. Zheng SS et al. Orthotopic liver transplantation for patiens with Klatskin tumor. Hepatobiliary pancreat Dis Int 2005;4,1:28–31.
26. Friman S. Cholangiocarcinoma – current treatment options Scandinavian Journal of Surgery 2011;100:30–34.
27. Lamesch P, Weimann A, Hauss J et al. Surgical treatment of intrahepatic cholangiocarcinoma Chirurgie 1997;122(2):88–91.
28. Lau WY, Lai EC, Lau SH. Management of bile duct injury after laparoscopic cholecystectomy: a review. ANZ J Surg 2010;80(1-2):75–81.
29. Mirza DF, Narsimhan KL, Ferraz Neto BH et al. Bile duct injury following laparoscopic cholecystectomy: referral pattern and management. Br J Surg 1997;84(6):786–90.
30. de SantibáĖes E, Ardiles V, Pekolj J. Complex bile duct injuries: management. HPB (Oxford) 2008;10(1):4–12.
31. Ahrendt SA, Pitt HA. Surgical therapy of iatrogenic lesions of biliary tract. World J Surg 2001;25(10):1360–5.
32. Mercado MA, Domínguez I. Classification and management of bile duct injuries. World J Gastrointest Surg 2011;27,3(4):43–8.
33. Svab J, Peskova M. Latrogenic injuries of the bile ducts in laparoscopic cholecystectomia. Rozhl Chir 1996;75,1:41–46.
34. Svab J et al. Reoperation in iatrogenic injuries in the biliary tract. Bratisl Lek listy 1996;97,12:734–736.
35. Svab J, Peskova M, Krska Z. Prevention, diagnosis and surgical treatment of injuries of the biliary tract due laparoscopic cholecystectomy.Treatment of papilla injurie cause by invasive endoscopy. Rozhl Chir 200;84,4:182–190.
36. Balas V, Peskova M, Svab J. Reoperation on the biliary tract and its preventive. Rozhl Chir 1981;60,3:148-53.
37. Paul O, Vítek P, Peskova M, Andrýsek O. Surgical and technical aspects of regional chemotherapy by means of an arterial catheter port, Cas Lek Ces 1995;134,14:435–439.
38. McWiliams et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol 2010;21:204–213.
39. Nakagohri T, Kinoshita T, Konishi M et al. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg 2008;32(12):2675-80.
40. Hemming AW, Reed AI, Fujita S et al. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005;241(5):693–9;discussion 699–702.
41. Pessaux P, Chenard MP, Bachellier P et al. Consequences of chemotherapy on resection of colorectal liver metastases. J Visc Surg 2010;147(4):e193–201.
42. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11(1):38–47.
43. Pešková M, Šváb J, Hořejš J et al. Možnosti ovlivnění metastatických nádorů jater. Sb Lek 2002;103(2):167–71.
44. Krška Z, Šváb J, Ulrych J. Nádory jater – možnosti chirurgické léčby. Staškovy dny, 2009, předn + Sborník.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2012 Číslo 9
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
Najčítanejšie v tomto čísle
- A giant gastrointestinal stromal tumour – a case report
- Diverticulum of the greater curvature of the stomach as a cause of anaemisation
- The development of surgical treatment in liver and biliary tract diseases
- SILS appendectomy for acute appendicitis – two-year experience